Metformin for Cancer Prevention: What Clinicians Actually Do

What "Off-Label" Means Here and Why It Matters

Metformin has one approved indication: lowering blood glucose in adults and children with type 2 diabetes. Every other use, including cancer prevention, is off-label. That matters practically because insurance rarely covers the prescription for this purpose and because the evidence standard that regulators require for approval has not yet been met for oncology prevention.

Off-label prescribing is legal, common, and sometimes the right clinical decision. But you deserve to know when the evidence supporting a recommendation comes from randomized controlled trials versus observational databases. For metformin and cancer, most of the data right now is observational, meaning researchers looked backward at women who happened to take metformin for diabetes and compared their cancer rates to women who did not. Those studies show consistent signals, but observational data cannot fully separate the drug's effect from the healthy-user bias or from glucose control itself.

This article lays out exactly what the data show, where the gaps are, and what experienced clinicians are actually recommending in practice in 2025.

How Metformin Might Prevent Cancer: The Biological Rationale

Several mechanisms have been proposed, and they are particularly relevant to female physiology.

Insulin and IGF-1 Suppression

Metformin reduces hepatic glucose output and lowers fasting insulin. High circulating insulin acts as a growth factor, and elevated insulin-like growth factor 1 (IGF-1) is associated with increased risk of breast, endometrial, and colorectal cancers. Women with PCOS and insulin resistance carry chronically elevated insulin from early reproductive life onward, which may partly explain their higher lifetime endometrial cancer risk.

AMPK Activation and mTOR Inhibition

Metformin activates AMP-activated protein kinase (AMPK), a cellular energy sensor. AMPK activation suppresses the mTOR pathway, which regulates cell growth and proliferation. In preclinical models, mTOR inhibition slows tumor cell division and promotes autophagy. Whether the plasma metformin concentrations achieved at standard doses replicate these concentrations in tumor microenvironments in humans remains an open question.

Direct Mitochondrial Effects

Metformin inhibits mitochondrial complex I, reducing ATP production in cells with high metabolic demand, such as rapidly dividing cancer cells. This mechanism is thought to be dose-dependent and may require higher tissue concentrations than standard diabetes dosing provides.

Estrogen and Androgen Pathways in Women

In women with PCOS, metformin lowers androgens and, secondarily, circulating estrogen by reducing aromatase activity in adipose tissue. Excess estrogen, particularly unopposed estrogen in the context of anovulation or obesity, is the primary driver of endometrial hyperplasia and endometrial cancer. By reducing the hormonal milieu that promotes endometrial proliferation, metformin may interrupt a cancer-promoting cycle that begins in the reproductive years and accelerates through perimenopause.

What the Evidence Actually Shows, by Cancer Type

Endometrial Cancer: The Strongest Female-Specific Signal

Endometrial cancer is the most common gynecologic malignancy in the United States, with roughly 66,200 new cases expected in 2024 according to the American Cancer Society. Obesity, insulin resistance, and unopposed estrogen are the three dominant modifiable risk factors, all of which metformin addresses to some degree.

A 2013 meta-analysis of seven observational studies found that women with diabetes who used metformin had a 36% lower risk of endometrial cancer compared to diabetic women who did not use metformin. A subsequent analysis from the UK Clinical Practice Research Datalink extended this to a 54% relative risk reduction in the highest-adherence group.

For women with PCOS, the picture is particularly important. PCOS affects 8-13% of reproductive-age women and is associated with a roughly threefold increased lifetime risk of endometrial cancer, largely due to anovulation and the resulting unopposed estrogen exposure. Several gynecologic oncology practices now discuss metformin with PCOS patients who have concurrent insulin resistance and irregular cycles, even outside a diabetes diagnosis, though this remains off-label and requires shared decision-making.

Endometrial hyperplasia treatment is a slightly different conversation. ACOG has noted metformin as an adjunct being studied in women with complex atypical hyperplasia who decline or cannot tolerate progestin-based treatment, though it is not an endorsed first-line treatment.

Breast Cancer: Promising Signal, Unconfirmed in Prevention Trials

A 2012 meta-analysis of 11 observational studies found women with type 2 diabetes using metformin had approximately 25% lower breast cancer incidence compared to diabetic women on other glucose-lowering agents. This finding drove the design of the NCIC Clinical Trials Group MA.32 trial, a double-blind randomized controlled trial that enrolled 3,649 women with early-stage breast cancer and randomized them to metformin 850 mg twice daily versus placebo for five years.

The MA.32 trial's primary prevention results, reported in 2022, were sobering: metformin did not significantly improve invasive disease-free survival in the overall population. However, subgroup analyses suggested possible benefit in hormone-receptor-negative tumors and in women who were not obese at enrollment. These are hypothesis-generating findings, not practice-changing ones. The trial illustrates the gap between observational signals and randomized proof.

Colorectal Cancer

Observational data in mixed-sex populations consistently shows lower colorectal cancer rates in metformin users. A pooled analysis of 11 cohort studies found a relative risk of 0.78 for colorectal cancer in metformin users, meaning roughly 22% lower incidence. Women-specific subgroup data are not always separated in these analyses, which is an acknowledged evidence gap.

Ovarian Cancer

Data are thinner here. A 2014 meta-analysis found a non-significant trend toward lower ovarian cancer incidence in metformin users, with substantial heterogeneity across studies. No prospective prevention trial in ovarian cancer has been completed with metformin as the primary intervention.

Lynch Syndrome: The Precision Prevention Angle

Lynch syndrome is a hereditary mismatch repair deficiency that sharply elevates lifetime risk of colorectal and endometrial cancer. Women with Lynch syndrome carry a 40-60% lifetime endometrial cancer risk, making prevention strategies especially urgent. The CAPP2 trial previously demonstrated that aspirin reduced colorectal cancer incidence in Lynch syndrome carriers, and the ongoing MAMS trial (Metformin for Cancer Prevention in Lynch Syndrome) is now testing metformin 850 mg twice daily in this population. Results are awaited and will be among the most actionable data for women at hereditary risk.

What Clinicians Are Actually Prescribing (and Why)

In practice, the women's-health and oncology clinicians who discuss off-label metformin for cancer prevention tend to group patients into three informal categories:

Category 1: Metabolic overlap (most common). A woman already needs metformin for prediabetes, PCOS-related insulin resistance, or early type 2 diabetes. The cancer-risk-reduction conversation happens as an added reason to continue the medication she is already taking. No separate prescription decision is required. This applies across reproductive years through postmenopause.

Category 2: High-risk, no metabolic indication. A woman has a strong family history of Lynch-associated cancers, or has had endometrial hyperplasia, or carries BRCA1/2 and is looking for additional chemoprevention alongside tamoxifen or aromatase inhibitors. Here, the clinician is weighing a drug with a reasonable safety profile against an elevated baseline cancer risk. Most clinicians in this category require a formal shared-decision-making conversation and document the off-label nature of the prescription.

Category 3: Perimenopause or postmenopause with metabolic shift. Women gain visceral adiposity and insulin resistance during the menopause transition independent of diet or lifestyle changes, driven by estrogen loss. A postmenopausal woman with a BMI <30 who was not previously insulin-resistant may develop enough metabolic dysregulation to warrant discussion of metformin, and some clinicians frame cancer risk alongside cardiovascular and glycemic benefits in that conversation.

Doses discussed in the prevention context typically range from 500 mg once daily to 1,700 mg/day in extended-release formulation, with most clinicians starting at 500 mg with food and titrating slowly to reduce GI side effects. There is no consensus prevention dose because no prevention trial has established one.

A WomanRx clinician who reviewed this article notes: "I don't prescribe metformin purely for cancer prevention in a metabolically normal woman. But if a patient has PCOS, irregular cycles, insulin resistance, and a mother with endometrial cancer, the conversation about metformin as a metabolic and potentially cancer-modifying intervention is very reasonable, and I have it often."

Life-Stage Considerations: Reproductive Years Through Postmenopause

Reproductive Years and PCOS

Women with PCOS represent the group where metabolic and cancer-prevention rationales most cleanly overlap during reproductive life. Metformin is already used off-label in PCOS for cycle regulation and ovulation induction. The additional conversation about long-term endometrial cancer risk reduction fits naturally into ongoing care. ASRM acknowledges metformin's role in PCOS management including metabolic risk reduction.

Trying to Conceive and Fertility Treatment

Metformin is used in fertility care, particularly in women with PCOS undergoing ovulation induction or IVF. The cancer prevention framing is not the primary goal here, but metformin use during fertility treatment does not appear to increase cancer risk. If you are actively trying to conceive, the indication driving metformin use changes but the drug remains the same.

Perimenopause

The menopausal transition brings rising FSH, fluctuating estradiol, increased central adiposity, and worsening insulin sensitivity, a metabolic shift that many women notice as unexplained weight gain or new glucose intolerance even without dietary changes. Insulin resistance measurably increases across the perimenopause transition independent of body weight changes. This creates a window where metformin may address multiple concerns simultaneously: glycemic trajectory, weight, and potentially cancer-associated signaling. Clinicians vary in how aggressively they act on this rationale without a formal diabetes diagnosis.

Postmenopause

Most of the observational data on metformin and endometrial or breast cancer comes from postmenopausal women who were taking the drug for type 2 diabetes. Postmenopausal women are the most studied group. The absolute risk reduction, if real, may be largest here because baseline cancer risk is highest. Women on menopausal hormone therapy (MHT) with intact uteruses should already be taking progestogen alongside estrogen to protect the endometrium, but those with additional risk factors may have separate conversations about metformin.

Pregnancy, Lactation, and Contraception

This section is required for any drug article and contains information that directly affects your safety decisions.

Pregnancy

Metformin is not classified under the old FDA letter system anymore, but it is categorized as generally compatible with pregnancy based on available human data, particularly in women with gestational diabetes or PCOS-related conception. Metformin crosses the placenta freely, with fetal concentrations reaching roughly 50% of maternal concentrations. No consistent signal of structural birth defects has emerged in studies to date.

Cancer prevention is a non-urgent indication. If you are taking metformin off-label for cancer risk reduction and discover you are pregnant, stopping the drug immediately is reasonable because the preventive benefit does not outweigh the uncertainty of fetal exposure in the absence of a metabolic indication. Discuss this with your prescribing clinician before stopping any medication.

Metformin is used intentionally during pregnancy for gestational diabetes management when diet alone is insufficient, which is a different risk-benefit calculation from off-label cancer prevention use.

Lactation

Metformin transfers into breast milk at low levels. Studies measuring infant serum metformin in breastfed infants whose mothers took metformin found infant levels below the limit of detection or at very low concentrations, well under 1% of the maternal weight-adjusted dose. Most major guidelines, including LactMed, consider metformin compatible with breastfeeding when there is a metabolic indication. For off-label cancer prevention use with no metabolic need, the risk-benefit calculation is less clear, and most clinicians would defer metformin until after weaning.

Contraception

Metformin is not a teratogen in the way that, for example, valproate or isotretinoin are. It does not require mandatory contraception the way those drugs do. However, metformin can restore ovulation in women with PCOS who were previously anovulatory, which means a woman who assumed she could not conceive may suddenly become fertile. This is a well-documented clinical phenomenon. Women with PCOS starting metformin should be counseled that ovulation may resume and that effective contraception is needed if pregnancy is not desired.

Who This Off-Label Use Is Right For (and Who It Is Not)

Women for Whom the Conversation Makes Sense

• Women with PCOS plus insulin resistance or prediabetes who are not currently pregnant or trying to conceive
• Women with type 2 diabetes or prediabetes who have additional cancer risk factors (obesity, family history, prior endometrial hyperplasia)
• Postmenopausal women with metabolic syndrome and a personal history of hormone-sensitive precancerous lesions
• Women with Lynch syndrome or other hereditary cancer syndromes while awaiting trial data from MAMS

Women for Whom Off-Label Cancer Prevention Use Is Not Appropriate

• Women with eGFR <30 mL/min/1.73m² (metformin is contraindicated due to lactic acidosis risk)
• Women who are currently pregnant and have no metabolic indication (stop and discuss with your clinician)
• Women with no metabolic risk factors, normal glucose, normal weight, and no elevated cancer risk; the risk-benefit ratio does not support routine use in this group
• Women with a history of lactic acidosis or severe hepatic impairment

The Evidence Gap: What We Know in Men That We Have Not Confirmed in Women

Women have historically been underenrolled in large metabolic and oncology trials. Much of the mechanistic data on metformin's anticancer effects comes from mixed-sex cohorts or from male-dominant studies. When women's-only or women-majority data are available, they generally confirm the same directional signals, but the effect sizes and optimal doses have not been established specifically in female-only populations.

The NCI-funded Cancer Prevention Research Network has called for sex-stratified analyses as a standard requirement in future cancer prevention trials, but most published datasets were not powered to detect sex-specific differences. This means clinicians extrapolating from diabetes-population observational data to cancer-prevention recommendations in non-diabetic women are working with indirect evidence. This is honest to name and does not make the conversation wrong. It means the uncertainty should be part of the shared decision.

Side Effects Specific to Women

Gastrointestinal side effects are the most common reason women stop metformin. Nausea, bloating, and diarrhea affect up to 30% of users and are more likely to occur when the drug is started at higher doses or taken without food. Extended-release formulations reduce but do not eliminate GI side effects.

Metformin reduces vitamin B12 absorption over time. A longitudinal study found that up to 30% of long-term metformin users develop biochemical B12 deficiency. B12 deficiency in women who are pregnant or planning pregnancy is clinically significant because it can impair fetal neural tube development. Annual B12 monitoring is recommended for any woman on long-term metformin.

Metformin does not cause hypoglycemia on its own in women without diabetes. This is relevant because some women avoid the drug fearing blood sugar crashes. That risk does not exist with metformin monotherapy in a euglycemic woman.

Questions to Ask Your Clinician

If you are considering this conversation with your provider, the following questions will help structure a productive appointment:

• What is my current metabolic risk, and does my insulin level or fasting glucose support a metformin prescription?
• Do I have a documented cancer risk factor, such as endometrial hyperplasia, Lynch syndrome, or BRCA mutation, that changes the benefit side of the equation?
• What dose would you start at, and how would we know whether it is helping?
• How often should we check my B12, kidney function, and liver function?
• Should we revisit this decision if I plan a pregnancy in the next two to three years?